Clinical Trials Logo

Filter by:
NCT ID: NCT01746654 Completed - Clinical trials for Bacterial Infections

Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

Start date: December 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether the antibacterial protein P128 is (i) safe and well tolerated in healthy volunteers and in chronic kidney diseases patients on dialysis, (ii) is it effective in reducing the nasal carriage of pathogen (Staphylococcus aureus) in humans.

NCT ID: NCT01746017 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of LY2922470 in Healthy Participants and Participants With Diabetes

Start date: December 2012
Phase: Phase 1
Study type: Interventional

The aim of this trial is to evaluate the safety of the study drug in healthy participant and participant with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study consists of two parts. Part A will study healthy participants in up to 4 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 5 weeks.

NCT ID: NCT01743677 Completed - Healthy Clinical Trials

CP-690,550 Thorough QTc Study

Start date: October 26, 2007
Phase: Phase 1
Study type: Interventional

ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine whether intensive monitoring of QT interval in target patient populations is required during later stages of development. The current study is designed to ascertain whether CP-690,550 is associated with QTc prolongation.

NCT ID: NCT01742299 Active, not recruiting - GIST and CML Clinical Trials

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Start date: March 26, 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to allow continued use of imatinib in patients who are on imatinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator.

NCT ID: NCT01741181 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2

DIMENSION
Start date: September 2012
Phase: Phase 4
Study type: Interventional

Background and Objectives : The presence of vitamin D deficiency in patients with type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD). We aim to see whether supplementation of vitamin D in these patients helps to improve the endothelial function (EF) a surrogate marker of CVD risk. Hypothesis: Vitamin D supplementation in patients with T2DM and low serum 25(OH) D concentrations (<30ng/ml) will improve EF as measured by the Endo-PAT machine by 0.4 units (30% improvement over baseline) and/or will result in a increase of EPCs (CD133+/KDR+) and CD45dim CD34+/KDR. The investigators will test this hypothesis by comparing 2 groups of T2DM patients randomized to placebo or vitamin D3 for 16 weeks. Methods: This is a 16 weeks trial in which 120 T2DM patients will be screened with the aim to recruit 60 T2DM patients with vitamin D deficiency or insufficiency. Out of these 60 patients , 30 patients will be started on vitamin D supplementation and 30 patients will be given a matched placebo. Endothelial function (EF) will be checked before and after supplementation to see a change in EF. Significance of Project: If this study shows a significant improvement of EF, it would justify larger scale studies to show that vitamin D supplementation in patients with T2DM mitigates CVD risk and vitamin D supplementation in patients with T2DM and vitamin D deficiency to improve CVD risk.

NCT ID: NCT01739894 Recruiting - Gastric Cancer Clinical Trials

Feasibility Study of Intraperitoneal Paclitaxel

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This is a single arm phase 2 trial evaluating the efficacy and tolerability of intraperitoneal paclitaxel with oxaliplatin and capecitabine in advanced gastric cancer patients with peritoneal metastasis and/or cancer cells on peritoneal cytology. Twenty patients will be recruited into the study for an estimated period of two years. Paclitaxel will be administered intraperitoneally at 40mg/m2 on Day 1 and 8 in patients receiving standard intravenous oxaliplatin 130mg/m2 on Day 1 and capecitabine 1000mg/m2 on day 1-14. The study hypothesizes that the addition of intraperitoneal paclitaxel with chemotherapy will improve treatment efficacy.

NCT ID: NCT01739881 Recruiting - Lung Cancer Clinical Trials

Evaluating the Pulmonary Nodule With Imaging and Biomarkers

Start date: April 2011
Phase: N/A
Study type: Interventional

The study aims to determine if there are defining EBUS and confocal endoscopy features as well as exhaled alveolar gas VOC that can discriminate malignant pulmonary nodules or masses from benign etiology, thereby obviating unnecessary thoracotomy. Directly sampled alveolar gas VOC from patients with lung cancer will be compared against exhaled breath VOC for signature compounds that may complement CT in screening the population at risk.

NCT ID: NCT01738399 Completed - Insulin Resistance Clinical Trials

Coffee and Metabolic Health Outcomes

COMETH
Start date: April 2012
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the long-term (24 weeks) effects of coffee consumption on insulin sensitivity in insulin resistant individuals.

NCT ID: NCT01737827 Terminated - Clinical trials for Advanced Hepatocellular Carcinoma With c-MET Dysregulation

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Start date: March 25, 2013
Phase: Phase 2
Study type: Interventional

This study is to find out if INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway.

NCT ID: NCT01736410 Completed - Clinical trials for HER 2 Positive Advanced Gastric Cancer

A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Start date: May 2010
Phase: Phase 2
Study type: Interventional

To explore overall response rate of trastuzumab combined with TS-ONE based chemotherapy in first-line HER2-positive advanced gastric cancer.